Thus, the insertion of the anti-PD-L1 scFv in 53L10 can lead not only to higher binding ability to tumor cells, but can also significantly potentiate the activation of T cells and consequent tumor cell killing by efficiently interfering with the increased PD-L1-PD-1 interaction (see Supplementary Fig. 2). This evidence concerns the gene PDCD1 and neoplasm.